TORONTO, March 24, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF) today announced it will release its 2013 year-end financial results on Monday, March 31, 2014, before market open. The Company will subsequently hold a conference call on Monday, March 31, 2014, at 8:30 a.m. ET hosted by Mr.Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update.
|CONFERENCE CALL DETAILS|
|DATE:||Monday, March 31, 2014|
|TIME:||8:30 a.m. ET|
|DIAL-IN NUMBER:||(647) 427-7450 or (888) 231-8191|
|TAPED REPLAY:||(416) 849-0833 or (855) 859-2056|
This call is being webcast and can be accessed from the Concordia website at www.concordiarx.com. An archived replay of the webcast will be available for one year.
Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs and medical devices for the diabetic population. The company's legacy pharmaceutical business consists of an ADHD-treatment drug, Kapvay® (clonidine extended release tablets), Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets). Concordia'sSpecialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin® in the United States.
Concordia operates out of facilities in Oakville, Ontario, Lenexa, Kansas (near Kansas City, Missouri), Bannockburn, (near Chicago), Illinois and Bridgetown, Barbados.
SOURCE Concordia Healthcare Corp.
For further information:
For more information, please visit www.concordiarx.com or contact:
Kristen Van Vogt
416-815-0700 x 244
416-815-0700 x 225